Table 4.
Multivariate Cox regression analysis of overall survival in patients with non-small cell lung cancer
| RR | 95% CI | p Value | |
| Clinical stage | |||
| III (A and B) | 1 | – | 0.130 |
| I–II | 0.567 | 0.272 to 1.182 | |
| N stage | |||
| N0 | 1 | – | 0.066 |
| N1–3 | 2.165 | 0.951 to 4.928 | |
| p53 | |||
| Negative | 1 | – | 0.645 |
| Positive | 1.062 | 0.822 to 1.371 | |
| p27 | |||
| Negative | 1 | – | 0.427 |
| Positive | 0.901 | 0.684 to 1.1.65 | |
| pRb2/p130 | |||
| Negative | 1 | – | 0.0001 |
| Positive | 0.525 | 0.395 to 0.697 | |
| p16 | |||
| Positive | 1 | – | 0.005 |
| Negative | 0.635 | 0.462 to 0.872 | |
| Cyclin D1 | |||
| Negative | 1 | – | 0.001 |
| Positive | 1.749 | 1.251 to 2.447 |
CI, confidence interval; pRb, retinoblastoma protein; RR, relative risk of death.